Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Q3 2026 Earnings Presentation
18 slides from Quidelortho's earnings presentation, Nov 3, 2026
Slide 1: QuidelOrtho Third Quarter 2026 Financial Results
November 3, 2026 QuidelOrtho Third Quarter 2026 Financial Results © 2026 QuidelOrtho Corporation. All rights reserved. | 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are
Slide 3: Basis of Presentation
Basis of Presentation ▪ 2026 financials are as of the three and nine months ended September 27, 2026 and 2025 financials are as of the three and nine months ended September 28, 2025. ▪ Revenue growth rates are shown on a constant currency basis unless otherwise noted. The term "constant currency" me
Slide 4: Q3 2026 Revenue Highlights
Q3 2026 Revenue Highlights Across Highly Across Key Healthcare Recurring Regions Settings Revenue Molecular 1% Donor Screening –% North America 54% Latin America 12% Instruments 4% Immunohematology 23% JPAC 12% $619M $619M $619M (12)% y/y (12)% y/y (12)% y/y Constant Currency Constant Currency China
Slide 5: YTD 2026 Revenue Highlights
YTD 2026 Revenue Highlights Across Highly Across Key Healthcare Recurring Regions Settings Revenue Molecular 1% Donor Screening 1% North Latin America 11% Instruments 4% America 53% Immunohematology 22% JPAC 12% $1.87B $1.87B $1.87B (8)% y/y (8)% y/y (8)% y/y Constant Currency Constant Currency Cons
Slide 6: Q3 2026 Financial Results
Q3 2026 Financial Results Adj Operating Expenses Adj EBITDA Adj Diluted EPS Cash $210M $148M $0.31 $166M Adj. EBITDA Margin Free Cash Flow (3)% y/y 23.9% (61)% y/y $0.3M SM&A Adj Gross Profit Margin Adj Tax Rate Total Net Debt $170M | (3)% y/y 47.8% | (90) bps y/y 27.4% $2.8B Net Debt to Adj EBITDA
Slide 7: YTD 2026 Financial Results
YTD 2026 Financial Results Adj Operating Expenses Adj EBITDA Adj Diluted EPS Free Cash Flow $656M $386M $0.41 $(203)M Adj. EBITDA Margin (1)% y/y 20.6% (75)% y/y (20)% y/y SM&A Adj Gross Profit Margin Adj Tax Rate Operating Cash Flow $529M | 1% y/y 45.3% | (300) bps y/y 26.7% $(124)M Capital Expendi
Slide 8: FY 2026 Financial Guidance
FY 2026 Financial Guidance Financial Guidance Updated (As of 11/3/2026) Previous (As of 8/6/2026) Total Revenues (Reported) $2.52 - $2.54B $2.52 - $2.60B Adjusted EBITDA $540 - $545M $540 - $560M Adjusted EBITDA Margin ~21% 21% - 22% Adjusted Diluted EPS $0.65 - $0.70 $0.65 - $0.90 Key Assumptions ▪
Slide 9: Appendix
Appendix © 2026 QuidelOrtho Corporation. All rights reserved. | 9
Slide 10: Non-GAAP Adjustments
Non-GAAP Adjustments Fiscal Quarter Year to Date In millions Q3 2026 Q3 2025 Q3 2026 Q3 2025 Employee compensation charges $ 1.4 $ — $ 5.8 $ — Accelerated depreciation 2.0 1.5 6.1 2.5 Incremental depreciation on PP&E fair value adjustment 1.8 3.2 5.3 9.8 Amortization of deferred cloud computing impl
Slide 11: Q3 2026 Non-GAAP Reconciliation
Q3 2026 Non-GAAP Reconciliation Fiscal Quarter Q3 2026 Fiscal Quarter Q3 2025 In millions GAAP Adjustments (1) Non-GAAP GAAP Adjustments (1) Non-GAAP Gross profit $ 289.6 $ 6.4 $ 296.0 $ 335.6 $ 5.4 $ 341.0 Selling, marketing and administrative 182.7 (12.7) 170.0 186.9 (11.3) 175.6 Research and deve
Slide 12: Q3 2026 YTD Non-GAAP Reconciliation
Q3 2026 YTD Non-GAAP Reconciliation Year to Date Q3 2026 Year to Date Q3 2025 In millions GAAP Adjustments (1) Non-GAAP GAAP Adjustments (1) Non-GAAP Gross profit $ 826.3 $ 20.8 $ 847.1 $ 953.8 $ 14.6 $ 968.4 Selling, marketing and administrative 571.7 (43.0) 528.7 551.9 (26.1) 525.8 Research and de
Slide 13: Revenue by Geography
Revenue by Geography Three Months Ended $ in millions 2025 2026 Third Quarter Q1 Q2 Q3 Q4 Q1 Q2 Q3 Percent Currency Constant Change Impact Currency (1) North America $406.7 $310.7 $381.4 $390.1 $328.9 $327.4 $330.7 (13.3)% 0.1% (13.4)% EMEA 88.9 87.3 91.8 92.7 92.5 91.2 86.9 (5.3)% (2.5)% (2.8)% Chi
Slide 14: Revenue by Business Unit
Revenue by Business Unit Three Months Ended $ in millions 2025 2026 Third Quarter Q1 Q2 Q3 Q4 Q1 Q2 Q3 Percent Currency Constant Change Impact Currency (1) Labs $373.0 $369.7 $373.8 $389.2 $353.1 $382.9 $353.2 (5.5)% 0.4% (5.9)% Immunohematology 128.5 132.3 142.0 141.0 138.3 134.2 142.0 —% (0.9)% 0.
Slide 15: Revenue by Respiratory and Non-Respiratory
Revenue by Respiratory and Non-Respiratory Three Months Ended $ in millions 2025 2026 Third Quarter Q1 Q2 Q3 Q4 Q1 Q2 Q3 Percent Currency Constant Change Impact Currency (1) Respiratory Revenue $119.8 $46.7 $112.3 $123.3 $67.9 $47.9 $68.8 (38.7)% —% (38.7)% Non-Respiratory Revenue 573.0 567.2 587.6
Slide 16: Non-GAAP Reconciliations
Non-GAAP Reconciliations Three Months Ended $ in millions September 27, 2026 September 28, 2025 Percent Change Currency Impact Constant Currency (1) Total revenues $618.9 $699.9 (11.6)% —% (11.6)% In millions Respiratory 68.8 112.3 (38.7)% —% (38.7)% China excluding respiratory 48.4 84.4 (42.7)% 3.2
Slide 17: Non-GAAP Reconciliations – Adjusted EBITDA
Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Quarter Year to Date In millions Q3 2026 Q3 2025 Q3 2026 Q3 2025 Net loss $ (53.8) $ (733.0) $ (238.5) $ (1,001.1) Depreciation and amortization 119.6 112.1 349.2 329.5 Interest expense, net 55.4 46.1 161.2 126.6 (Benefit from) provision for income t
Slide 18: quidelortho.com
ae See MEUILE) quidelortho.co